Key result
Higher blood CSF1 linked to ~18% higher CAD risk per SD.
Why the study?
Many biomarker-CAD associations may result from reverse causation or confounding, so Mendelian randomization is needed to identify true causal mediators of CAD.
Are genetically determined blood levels of CSF1 and CXCL12 causal mediators of coronary artery disease?
Observational
Yes
Are genetically determined blood levels of CSF1 and CXCL12 causal mediators of coronary artery disease?
The identification of CSF1 and CXCL12 as causal mediators of coronary artery disease provides novel insights into the inflammatory mechanisms of CAD and highlights potential new therapeutic targets for prevention.
Answers are grounded in this paper and cite their sources.
MR identifies candidate causal CAD biomarkers; leaves open whether targeting them improves outcomes.
Background Identification of biomarkers that cause coronary artery disease (CAD) has led to important advances in prevention and treatment. Epidemiological analyses have identified many biomarker-CAD relationships; however, these associations may arise from reverse causation and/or confounding and therefore may not represent true causal associations. Mendelian randomization (MR) analyses overcome these limitations. Objectives This study sought to identify causal mediators of CAD through a comprehensive screen of 237 biomarkers using MR. Methods MR was performed by identifying genetic determinants of 227 biomarkers in ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial participants (N = 4,147) and combining these with genetic effects on CAD from the CARDIoGRAM consortium (60,801 cases and 123,504 controls). Blood concentrations of novel biomarkers identified by MR were then tested for association with incident major adverse cardiovascular events in ORIGIN. Results Six biomarkers were found to be causally linked to CAD after adjustment for multiple hypothesis testing. The causal role of 4 of these is well documented, whereas macrophage colony-stimulating factor 1 (CSF1) and stromal cell–derived factor 1 (CXCL12) have not previously been reported, to the best of our knowledge. MR analysis predicted an 18% higher risk of CAD per SD increase in CSF1 (odds ratio: 1.18; 95% confidence interval: 1.08 to 1.30; p = 2.1 × 10 −4 ) and epidemiological analysis identified a 16% higher risk of major adverse cardiovascular events per SD (hazard ratio: 1.16; 95% confidence interval: 1.09 to 1.23; p < 0.001). Elevated CXCL12 levels were also identified as a causal risk factor for CAD with consistent epidemiological results. Furthermore, genetically predicted CSF1 and CXCL12 levels were associated with CAD in the UK Biobank (n = 343,735). Conclusions The study identified CSF1 and CXCL12 as causal mediators of CAD in humans. Understanding the mechanism by which these markers mediate CAD will provide novel insights into CAD and could lead to new approaches to prevention. These results support targeting inflammatory processes and macrophages, in particular, to prevent CAD, consistent with the recent CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study). (Outcome Reduction With Initial Glargine Intervention [ORIGIN]; NCT00069784 )
No takes yet. Share an insight, caveat, or question.
Sjaarda et al. (2018) conducted an observational in Coronary Artery Disease (CAD). Blood CSF1 and CXCL12 was evaluated on Coronary artery disease (OR 1.18, 95% CI 1.08 to 1.30, p=2.1 x 10^-4). A 1 standard deviation increase in blood CSF1 was causally associated with an 18% higher risk of coronary artery disease, with similar findings for CXCL12.
Synapse has enriched 10 related papers. Consider them for comparative context: